Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis
Circulation: Cardiovascular Interventions · 2024-09 · 17 (9)
DOI: 10.1161/circinterventions.124.014064 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2024-09. Verfasst von Wojciech Wańha und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland (W. Wańha, P.P., T.Z.P., W. Wojakowski). Hauptthemen laut MEDLINE: Sirolimus, Drug-Eluting Stents, Registries, Coronary Restenosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Evidence suggests that drug-coated balloons may benefit in-stent restenosis (ISR) treatment. However, the efficacy of new-generation sirolimus-coated balloon (SCB) compared with the latest generation drug-eluting stents (DESs) has not been studied in this setting. METHODS: All patients in the EASTBORNE (The All-Comers Sirolimus-Coated Balloon European Registry) and DEB-DRAGON (DEB vs Thin-DES in DES-ISR: Long Term Outcomes) registries undergoing percutaneous coronary intervention for DES-ISR were included in the study. The primary study end point was target lesion revascularization at 24 months. Secondary end points were major adverse cardiovascular events, all-cause death, myocardial infarction, and target vessel revascularization at 24 months. Our goal was to evaluate the efficacy and safety of SCB versus thin-struts DES in ISR at long-term follow-up. RESULTS: A total of 1545 patients with 1679 ISR lesions were included in the pooled analysis, of whom 621 (40.2%) patients with 621 lesions were treated with thin-strut DES and 924 (59.8%) patients with 1045 lesions were treated with SCB. The unmatched cohort showed no differences in the incidence of target lesion revascularization (10.8% versus 11.8%; P =0.568); however, there was a trend toward lower rates of myocardial infarction (7.4% versus 5.0%; P =0.062) and major adverse cardiovascular events (20.8% versus 17.1%; P =0.072) in the SCB group. After propensity score matching (n=335 patients per group), there were no significant differences in the rates of target lesion revascularization (11.6% versus 11.8%; P =0.329), target vessel revascularization (14.0% versus 13.1%; P =0.822), myocardial infarction (7.2% versus 4.5%; P =0.186), all-cause death (5.7% versus 4.2%; P =0.476), and major adverse cardiovascular event (21.5% versus 17.6%; P =0.242) between DES and SCB treatment. CONCLUSIONS: In patients with ISR, angioplasty with SCB compared with thin-struts DES is associated with comparable rates of target lesion revascularization, target vessel revascularization, myocardial infarction, all-cause death, and major adverse cardiovascular events at 2 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland (W. Wańha, P.P., T.Z.P., W. Wojakowski).
- DCB Academy, Milano, Italy (W. Wańha, S.I., B.C.).
- Department of Cardiology, Poznań University of Medical Sciences, Poland (S.I., M.L., M. Grygier).
- Department of Cardiology, Jagiellonian University Medical College, Kraków, Poland (R.J., S.B.).
- Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland (R.W., A.W.).
- Institute of Heart Diseases, Wrocław University Hospital, Poland (B.T., W.K., K.R., P.K.).
ORCID-Profile: Wojciech Wańha, Sylwia Iwańczyk, Rafał Januszek, Rafał Wolny, Brunon Tomasiewicz, Wiktor Kuliczkowski, Krzysztof Reczuch, Łukasz Kuźma, Piotr Kubler, Piotr Niezgoda, Jacek Kubica, Robert J Gil, Miłosz Jaguszewski, Maciej Wybraniec, Adam Witkowski, Fabrizio D'Ascenzo, Antonio Greco, Stanisław Bartuś, Maciej Lesiak, Marek Grygier, Wojciech Wojakowski, Bernardo Cortese
Zitieren
APA
Wańha, W., Iwańczyk, S., Januszek, R., Wolny, R., Tomasiewicz, B., Kuliczkowski, W., Reczuch, K., Pawlus, P., Pawłowski, T. Z., Kuźma, Ł., Kubler, P., Niezgoda, P., Kubica, J., Gil, R. J., Pawłowski, T. F., Gąsior, M., Jaguszewski, M., Wybraniec, M., Witkowski, A., …, & Cortese, B. (2024). Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis. Circulation: Cardiovascular Interventions, 17(9). https://doi.org/10.1161/circinterventions.124.014064
Vancouver
Wańha W, Iwańczyk S, Januszek R, Wolny R, Tomasiewicz B, Kuliczkowski W, et al. Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis. Circulation: Cardiovascular Interventions. 2024;17(9). doi:10.1161/circinterventions.124.014064
BibTeX
@article{Waha2024,
author = {Wańha, Wojciech and Iwańczyk, Sylwia and Januszek, Rafał and Wolny, Rafał and Tomasiewicz, Brunon and Kuliczkowski, Wiktor and Reczuch, Krzysztof and Pawlus, Paweł and Pawłowski, Tomasz Z and Kuźma, Łukasz and Kubler, Piotr and Niezgoda, Piotr and Kubica, Jacek and Gil, Robert J and Pawłowski, Tomasz F and Gąsior, Mariusz and Jaguszewski, Miłosz and Wybraniec, Maciej and Witkowski, Adam and Kowalewski, Mariusz and D'Ascenzo, Fabrizio and Greco, Antonio and Bartuś, Stanisław and Lesiak, Maciej and Grygier, Marek and Wojakowski, Wojciech and Cortese, Bernardo},
title = {Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis},
journal = {Circulation: Cardiovascular Interventions},
year = {2024},
volume = {17},
number = {9},
doi = {10.1161/circinterventions.124.014064}
}
EUVIMED